Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.
A González-CordónM DoménechM CamafortM Martínez-RebollarB TorresM LagunoJ RojasM LoncàJ L BlancoJ MallolasJ M GatellE de LazzariEsteban MartinezPublished in: HIV medicine (2018)
CIMT was a more sensitive marker of subclinical vascular disease progression than arterial stiffness in antiretroviral-naïve patients starting antiretroviral therapy with contemporary protease inhibitors. Classical risk factors but not antiretroviral therapy were associated with faster CIMT progression.
Keyphrases
- antiretroviral therapy
- end stage renal disease
- cardiovascular disease
- hiv infected
- risk factors
- ejection fraction
- human immunodeficiency virus
- chronic kidney disease
- newly diagnosed
- hiv aids
- hiv infected patients
- prognostic factors
- blood pressure
- metabolic syndrome
- coronary artery disease
- hepatitis c virus
- cardiovascular events
- patient reported